{"version":1,"type":"story","url":"https://digestai.news/story/endura-therapeutics-uses-ai-to-cut-drug-discovery-costs-by-triaging-50","json":"https://digestai.news/story/endura-therapeutics-uses-ai-to-cut-drug-discovery-costs-by-triaging-50.json","markdown":"https://digestai.news/story/endura-therapeutics-uses-ai-to-cut-drug-discovery-costs-by-triaging-50.md","slug":"endura-therapeutics-uses-ai-to-cut-drug-discovery-costs-by-triaging-50","headline":"Endura Therapeutics uses AI to cut drug discovery costs by triaging 500 diseases","summary":"Endura Therapeutics, a biotech company developing CRISPR-based pills, leverages AI to accelerate drug discovery by triaging 500 disease targets. Using language models, the team generated reports on each target, filtering based on prevalence, existing treatments, and potential efficacy. The first pass narrowed the list to about 100 diseases, with the second pass producing detailed analyses equivalent to decades of human effort. This approach reduces the time and cost of identifying viable drug candidates, enabling broader exploration of potential treatments without sacrificing depth in later stages.\n\nThe company’s method contrasts with traditional biotech practices, where teams focus on a small set of diseases due to resource constraints. By automating initial triage, Endura avoids early-stage mistakes and allocates resources more efficiently. Adrian Sanborn, CEO and co-founder, emphasizes that AI’s impact in science extends beyond data generation—it enables dynamic, iterative experimentation and internal tool-building, democratizing expertise that was previously inaccessible at scale.","keyPoints":["Endura used AI agents to analyze 500 diseases, generating reports to filter viable candidates in hours instead of years","First pass screened targets based on prevalence, existing treatments, and potential efficacy, narrowing to ~100 diseases","Second pass produced expert-level analyses, reducing human effort from decades to weeks while maintaining oversight"],"whyItMatters":"AI-driven triage cuts the cost and time of early-stage drug discovery, allowing biotech firms to explore broader disease landscapes without sacrificing rigor. This shifts the industry toward agile, data-driven decision-making, potentially accelerating breakthroughs in areas previously deemed too risky or resource-intensive.","category":{"slug":"research","name":"Research","url":"https://digestai.news/category/research"},"entities":{"companies":["Endura Therapeutics","Anthropic","Atomic AI"],"models":[],"people":["Adrian Sanborn","Roger Kornberg"]},"firstPublishedAt":"2026-09-24T15:03:16Z","updatedAt":"2026-09-24T15:03:16Z","sourceCount":1,"hasPrimarySource":false,"sources":[{"outlet":"Latent Space","title":"Foundries vs Navigators: Lowering the Cost of Science","url":"https://latent.space/p/foundries-vs-navigators-lowering","publishedAt":"2026-09-24T15:03:16Z","type":"newsletter","primary":false,"lead":true}],"sourceNotes":null,"discussions":[],"thread":null,"cite":{"text":"Digest AI, \"Endura Therapeutics uses AI to cut drug discovery costs by triaging 500 diseases\", 24 September 2026, https://digestai.news/story/endura-therapeutics-uses-ai-to-cut-drug-discovery-costs-by-triaging-50","publisher":"Digest AI","title":"Endura Therapeutics uses AI to cut drug discovery costs by triaging 500 diseases","datePublished":"2026-09-24T15:03:16Z","url":"https://digestai.news/story/endura-therapeutics-uses-ai-to-cut-drug-discovery-costs-by-triaging-50"},"generatedBy":"Written by Digest AI's editorial model from the linked sources; the sources are the record.","license":"Headlines, digests and key points are written by Digest AI and may be quoted with a link to the story page. Linked articles belong to their publishers. Terms: https://digestai.news/terms#reuse"}